International Niemann–Pick Disease Alliance

Menu

Trial Updates

Explore

Categories

  1. Cyclo Therapeutics’ Clinical Data Webinar Recording Available on Company Website

    • 29.05.20
    Read story

  2. Cyclo Therapeutics Inc. Announces Positive Top Line Results from Phase I Trial and Interim Analysis of Phase I/II Trial using Trappsol® Cyclo™ Intravenously to Treat Patients with Niemann-Pick Disease Type C1 (NPC1)

    • 21.05.20
    Read story

  3. Cyclo Therapeutics Announces Positive Feedback from European Medicines Agency on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1

    • 18.05.20
    Read story

  4. Cyclo Therapeutics Closes $2.0 Million Private Placement

    • 27.04.20
    Read story

  5. IntraBio Receives FDA Fast Track Designation for Niemann-Pick Disease

    • 25.03.20
    Read story

  6. Cyclo Therapeutics Inc. Announces Positive Safety Profile of its Drug Trappsol® Cyclo™ in the Treatment of Niemann Pick Disease Type C

    • 25.03.20
    Read story

  7. Cyclo Therapeutics Announces Positive Feedback from FDA on its Pivotal Trial Design for Trappsol® Cyclo™ for Niemann-Pick Disease Type C1

    • 02.03.20
    Read story

  8. Cyclo Therapeutics Announces Completion of Enrollment in its Phase I/II Trial to Evaluate Trappsol® Cyclo™ for the Treatment of Niemann-Pick Disease Type C

    • 20.02.20
    Read story

  9. Cyclo Therapeutics, Inc. Poster Presentation of Clinical Trial Data on Niemann-Pick Type C Disease at the 16th Annual WORLDSymposium Now Available

    • 05.02.20
    Read story

  10. Last Patient Last Visit in Cyclo Therapeutics’ Phase I Trial in Niemann-Pick Type C

    • 12.02.20
    Read story

Join the Registry

Calling all patients and carers! We've created a global registry of all NPD patients - if you're not enrolled yet, join us now...

The Impact of NPC

The global community tell their stories...